<p><strong>TELA Bio 任命 Joseph Capper 为指定董事长，并新增 Guido Neels、Guy Nohra 和 Paul Thomas 为董事会成员，几位现任董事将在 2026 年年度会议后退休。</strong></p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>个人</td>
<td>Doug Evans</td>
<td>Joseph Capper</td>
<td>Kurt Azarbarzin</td>
<td>Vince Burgess</td>
<td>Federica O’Brien</td>
<td>Guido Neels</td>
<td>Guy Nohra</td>
<td>Paul Thomas</td>
</tr>
<tr>
<td>职位</td>
<td>董事会主席</td>
<td>董事；当选后担任董事会主席</td>
<td>董事</td>
<td>董事</td>
<td>董事</td>
<td>二类董事</td>
<td>三类董事</td>
<td>三类董事</td>
</tr>
<tr>
<td>变更类型</td>
<td>将退休 / 不再连任</td>
<td>提名选举 / 将当选为主席</td>
<td>辞职</td>
<td>辞职</td>
<td>辞职</td>
<td>任命</td>
<td>任命</td>
<td>任命</td>
</tr>
<tr>
<td>生效日期</td>
<td>在 2026 年年度会议后立即生效</td>
<td>主席职位在 (i) Evans 辞职和 (ii) Capper 在 2026 年年度会议上当选后生效</td>
<td>在 2026 年年度会议后立即生效</td>
<td>在 2026 年年度会议后立即生效</td>
<td>在 2026 年年度会议后立即生效</td>
<td>在 2026 年年度会议后立即生效</td>
<td>在 2026 年年度会议后立即生效</td>
<td>在 2026 年年度会议后立即生效</td>
</tr>
<tr>
<td>原因</td>
<td>退休 / 不再连任</td>
<td>董事会提名选举；将担任主席</td>
<td>未披露</td>
<td>未披露</td>
<td>未披露</td>
<td>与辞职相关的董事会任命</td>
<td>与辞职相关的董事会任命</td>
<td>与辞职相关的董事会任命</td>
</tr>
<tr>
<td>替代信息</td>
<td>将由 Joseph Capper（当选后）替代</td>
<td>不适用</td>
<td>已进行接任任命（新任董事）</td>
<td>已进行接任任命（新任董事）</td>
<td>已进行接任任命（新任董事）</td>
<td>不适用</td>
<td>不适用</td>
<td>不适用</td>
</tr>
<tr>
<td>背景详情</td>
<td>未披露</td>
<td>在医疗科技/生命科学领域近 30 年；自 2023 年 1 月起担任 MiMedx 首席执行官；曾任 BioTelemetry 首席执行官（2010–2021）；前美国海军飞行员；拥有会计（西切斯特大学）和 MBA（乔治华盛顿大学）学位</td>
<td>未披露</td>
<td>未披露</td>
<td>未披露</td>
<td>自 2006 年以来担任 EW 的运营合伙人；曾任 Guidant 首席运营官；拥有董事会经验；拥有鲁汶大学学位和斯坦福大学 MBA</td>
<td>Alta Partners 的联合创始人；风险投资者；董事会职务；芝加哥大学 MBA；斯坦福大学学士</td>
<td>Prominex 的首席执行官和联合创始人；曾任 Roka Bioscience 和 LifeCell 首席执行官；Axogen 董事会成员；哥伦比亚大学 MBA；化学学士</td>
</tr>
<tr>
<td>董事会/委员会角色变更</td>
<td>将从薪酬和审计委员会退休</td>
<td>将担任主席；预计根据纳斯达克规则不具独立性</td>
<td>将辞去提名、薪酬、审计委员会职务</td>
<td>将辞去提名、薪酬、审计委员会职务</td>
<td>将辞去提名、薪酬、审计委员会职务</td>
<td>预计为薪酬和提名委员会成员</td>
<td>预计为审计委员会成员并担任薪酬委员会主席</td>
<td>预计为审计委员会成员并担任提名委员会主席</td>
</tr>
</tbody>
</table>
<p>原始 SEC 文件：TELA Bio, Inc. [ TELA ] - 8-K -2026 年 4 月 30 日
<strong>免责声明</strong></p>
<p>这是一个由人工智能生成的摘要，可能包含不准确的信息。请考虑与来源核实重要信息。请注意，此摘要仅基于提交给 SEC 的文件。</p>

TELA

<p>TELA Bio 已任命 Joseph Capper 为指定董事长，并新增 Guido Neels、Guy Nohra 和 Paul Thomas 为董事会成员。几位现任董事将在 2026 年年度会议后退休。Capper 将在选举后担任董事长，而新任命的董事将在现任董事辞职后填补相应职位。这一重组是 TELA Bio 持续治理变革的一部分</p>

<p><strong>TELA Bio appointed Joseph Capper as chairman-designate and added Guido Neels, Guy Nohra and Paul Thomas to its board, with several existing directors set to retire following the 2026 Annual Meeting.</strong></p>
<div class="lb-trans"><p><strong>TELA Bio 任命 Joseph Capper 为指定董事长，并新增 Guido Neels、Guy Nohra 和 Paul Thomas 为董事会成员，几位现任董事将在 2026 年年度会议后退休。</strong></p>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Individual</td>
<td>Doug Evans</td>
<td>Joseph Capper</td>
<td>Kurt Azarbarzin</td>
<td>Vince Burgess</td>
<td>Federica O’Brien</td>
<td>Guido Neels</td>
<td>Guy Nohra</td>
<td>Paul Thomas</td>
</tr>
<tr>
<td>Role</td>
<td>Chairman of the Board</td>
<td>Director; to serve as Chairman of the Board upon election</td>
<td>Director</td>
<td>Director</td>
<td>Director</td>
<td>Class II Director</td>
<td>Class III Director</td>
<td>Class III Director</td>
</tr>
<tr>
<td>Type of Change</td>
<td>Will retire / Not standing for re-election</td>
<td>Nominated for election / To be elected Chairman</td>
<td>Resigned</td>
<td>Resigned</td>
<td>Resigned</td>
<td>Appointed</td>
<td>Appointed</td>
<td>Appointed</td>
</tr>
<tr>
<td>Effective Date</td>
<td>Effective immediately following 2026 Annual Meeting</td>
<td>Chairman role effective upon (i) Evans' resignation and (ii) Capper's election at 2026 Annual Meeting</td>
<td>Effective immediately following 2026 Annual Meeting</td>
<td>Effective immediately following 2026 Annual Meeting</td>
<td>Effective immediately following 2026 Annual Meeting</td>
<td>Effective immediately following 2026 Annual Meeting</td>
<td>Effective immediately following 2026 Annual Meeting</td>
<td>Effective immediately following 2026 Annual Meeting</td>
</tr>
<tr>
<td>Reason</td>
<td>Retirement / not standing for re-election</td>
<td>Board nomination for election; to serve as Chairman</td>
<td>Not disclosed</td>
<td>Not disclosed</td>
<td>Not disclosed</td>
<td>Board appointment in connection with resignations</td>
<td>Board appointment in connection with resignations</td>
<td>Board appointment in connection with resignations</td>
</tr>
<tr>
<td>Replacement Info</td>
<td>To be replaced by Joseph Capper (upon election)</td>
<td>N/A</td>
<td>Successor appointments made (Incoming Directors)</td>
<td>Successor appointments made (Incoming Directors)</td>
<td>Successor appointments made (Incoming Directors)</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>Background Details</td>
<td>Not disclosed</td>
<td>Nearly 30 years in MedTech/life sciences; CEO of MiMedx since Jan 2023; former CEO of BioTelemetry (2010–2021); ex-U.S. Navy naval aviator; degrees in Accounting (West Chester) and MBA (George Washington)</td>
<td>Not disclosed</td>
<td>Not disclosed</td>
<td>Not disclosed</td>
<td>Operating Partner at EW since 2006; former COO of Guidant; board experience; degrees from University of Leuven and MBA from Stanford</td>
<td>Co-founder of Alta Partners; venture investor; board roles; MBA University of Chicago; BA Stanford</td>
<td>CEO and co-founder of Prominex; former CEO of Roka Bioscience and LifeCell; board member of Axogen; MBA Columbia; B.S. Chemistry</td>
</tr>
<tr>
<td>Board/Committee Role Changes</td>
<td>Will retire from Compensation and Audit Committees</td>
<td>Will serve as Chairman; not expected to be independent under Nasdaq rules</td>
<td>Will resign from Nominating, Compensation, Audit Committees</td>
<td>Will resign from Nominating, Compensation, Audit Committees</td>
<td>Will resign from Nominating, Compensation, Audit Committees</td>
<td>Expected member of Compensation and Nominating Committees</td>
<td>Expected member of Audit Committee and chair of Compensation Committee</td>
<td>Expected member of Audit Committee and chair of Nominating Committee</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>个人</td>
<td>Doug Evans</td>
<td>Joseph Capper</td>
<td>Kurt Azarbarzin</td>
<td>Vince Burgess</td>
<td>Federica O’Brien</td>
<td>Guido Neels</td>
<td>Guy Nohra</td>
<td>Paul Thomas</td>
</tr>
<tr>
<td>职位</td>
<td>董事会主席</td>
<td>董事；当选后担任董事会主席</td>
<td>董事</td>
<td>董事</td>
<td>董事</td>
<td>二类董事</td>
<td>三类董事</td>
<td>三类董事</td>
</tr>
<tr>
<td>变更类型</td>
<td>将退休 / 不再连任</td>
<td>提名选举 / 将当选为主席</td>
<td>辞职</td>
<td>辞职</td>
<td>辞职</td>
<td>任命</td>
<td>任命</td>
<td>任命</td>
</tr>
<tr>
<td>生效日期</td>
<td>在 2026 年年度会议后立即生效</td>
<td>主席职位在 (i) Evans 辞职和 (ii) Capper 在 2026 年年度会议上当选后生效</td>
<td>在 2026 年年度会议后立即生效</td>
<td>在 2026 年年度会议后立即生效</td>
<td>在 2026 年年度会议后立即生效</td>
<td>在 2026 年年度会议后立即生效</td>
<td>在 2026 年年度会议后立即生效</td>
<td>在 2026 年年度会议后立即生效</td>
</tr>
<tr>
<td>原因</td>
<td>退休 / 不再连任</td>
<td>董事会提名选举；将担任主席</td>
<td>未披露</td>
<td>未披露</td>
<td>未披露</td>
<td>与辞职相关的董事会任命</td>
<td>与辞职相关的董事会任命</td>
<td>与辞职相关的董事会任命</td>
</tr>
<tr>
<td>替代信息</td>
<td>将由 Joseph Capper（当选后）替代</td>
<td>不适用</td>
<td>已进行接任任命（新任董事）</td>
<td>已进行接任任命（新任董事）</td>
<td>已进行接任任命（新任董事）</td>
<td>不适用</td>
<td>不适用</td>
<td>不适用</td>
</tr>
<tr>
<td>背景详情</td>
<td>未披露</td>
<td>在医疗科技/生命科学领域近 30 年；自 2023 年 1 月起担任 MiMedx 首席执行官；曾任 BioTelemetry 首席执行官（2010–2021）；前美国海军飞行员；拥有会计（西切斯特大学）和 MBA（乔治华盛顿大学）学位</td>
<td>未披露</td>
<td>未披露</td>
<td>未披露</td>
<td>自 2006 年以来担任 EW 的运营合伙人；曾任 Guidant 首席运营官；拥有董事会经验；拥有鲁汶大学学位和斯坦福大学 MBA</td>
<td>Alta Partners 的联合创始人；风险投资者；董事会职务；芝加哥大学 MBA；斯坦福大学学士</td>
<td>Prominex 的首席执行官和联合创始人；曾任 Roka Bioscience 和 LifeCell 首席执行官；Axogen 董事会成员；哥伦比亚大学 MBA；化学学士</td>
</tr>
<tr>
<td>董事会/委员会角色变更</td>
<td>将从薪酬和审计委员会退休</td>
<td>将担任主席；预计根据纳斯达克规则不具独立性</td>
<td>将辞去提名、薪酬、审计委员会职务</td>
<td>将辞去提名、薪酬、审计委员会职务</td>
<td>将辞去提名、薪酬、审计委员会职务</td>
<td>预计为薪酬和提名委员会成员</td>
<td>预计为审计委员会成员并担任薪酬委员会主席</td>
<td>预计为审计委员会成员并担任提名委员会主席</td>
</tr>
</tbody>
</table>
</div><p>Original SEC Filing: TELA Bio, Inc. [ TELA ] - 8-K - Apr. 30, 2026
<strong>Disclaimer</strong></p>
<div class="lb-trans"><p>原始 SEC 文件：TELA Bio, Inc. [ TELA ] - 8-K -2026 年 4 月 30 日
<strong>免责声明</strong></p>
</div><p>This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.</p>
<div class="lb-trans"><p>这是一个由人工智能生成的摘要，可能包含不准确的信息。请考虑与来源核实重要信息。请注意，此摘要仅基于提交给 SEC 的文件。</p>
</div>

TELA Bio names Joseph Capper chairman; Guido Neels, Guy Nohra, Paul Thomas appointed to board

TradingView

TELA Bio 任命 Joseph Capper 为董事长，同时 Guido Neels、Guy Nohra 和 Paul Thomas 被任命为董事会成员